drugset / Trial / NCT06644417

Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBV) Infection

NCT06644417

Phase 2 Completed 122 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a phase II multicenter, randomized, double-blind, placebo controlled study designed to evaluate the efficacy and safety in LLV subjects and demonstrate that TQA3605 tablets combined with oral NAs drugs can improve the efficacy and safety of LLV subjects compared with oral NAs drug.

Timeline

Start
2024-11-14
Primary completion
2025-08-25
Completion
2025-12-10

Drugs

EvaluationDrugModalityDoseRoute
Subject TQA3605 Unknown 100 mg
Subject TQA3605 Unknown 200 mg